Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Zepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds
Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide),
What can't weight-loss meds do? Eli Lilly is going to test Zepbound as a treatment for addiction
Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster drug as a treatment for alcohol and drug addiction starting next year.
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.
Eli Lilly claims superiority of its weight-loss drug Zepbound after clinical trial
Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative areas of the pharmaceutical indus
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.
Eli Lilly is partnering with Ro to make it easier than ever to get Zepbound
Eli Lilly (LLY) has announced it will make lower-priced, single-dose vials of its popular weight-loss treatment Zepound available on telehealth platform Ro. Starting today, consumers can get an online diagnosis,
Ro, Eli Lilly to streamline patient access to Zepbound single-dose vials
Ro announced earlier that it is working with Eli Lilly (LLY) and Company to streamline access to Zepbound single-dose vials for Ro patients
7d
In new trial, Zepbound bests Wegovy for weight loss
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
BlackDoctor
2d
Zepbound Outperforms Wegovy in Weight Loss Clinical Trial
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
5d
Ozempic cuts drinking, Zepbound beats Wegovy, and a blood test detects 50 cancers: Pharma news roundup
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...
7d
Lilly’s Zepbound Beats Novo’s Wegovy in Head-to-Head Trial
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head ...
MM&M
7d
Lilly’s Zepbound tops Novo Nordisk’s Wegovy in head-to-head obesity study
The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback